Completed PHASE3 INTERVENTIONAL 2-arm NCT00228982

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections

Sponsor: Basilea Pharmaceutica

Conditions Skin Diseases, Bacterial Skin Diseases, Infectious Staphylococcal Skin Infections

Interventions Ceftobiprole medocaril Vancomycin

Updated 5 times since 2017 Last updated: Jul 25, 2012 Started: Oct 31, 2004 Primary completion: Dec 31, 2005 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Skin Diseases, Bacterial and Skin Diseases, Infectious, this trial is completed. The trial is conducted by Basilea Pharmaceutica and has accumulated 5 data snapshots since 2004. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Basilea Pharmaceutica

Data source: Basilea Pharmaceutica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.